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ABSTRACT  
Using Bayesian capture-recapture analysis, we estimated the number of current 
injecting drug users (IDUs) in Scotland in 2006 from the cross-counts of 5670 IDUs 
listed on four data-sources: social enquiry reports (901 IDUs listed), hospital records 
(953), drug treatment agencies (3504) and recent Hepatitis C virus (HCV) diagnoses 
(827 listed as IDU-risk). Further, we accessed exact numbers of opiate-related drugs-
related deaths (DRDs) in 2006+2007 to improve estimation of Scotland‟s DRD rates 
per 100 current IDUs.  
 
Using all four data-sources, and model-averaging of standard hierarchical log-linear 
models to allow for pairwise interactions between data-sources and/or demographic 
classifications, Scotland had an estimated 31700 IDUs in 2006 (95% credible interval: 
24900 to 38700); but 25000 IDUs (95% CI: 20700 to 35000) by excluding recent 
HCV diagnoses whose IDU-risk can refer to past injecting. Only in the younger age-
group (15-34 years) were Scotland‟s opiate-related DRD rates significantly lower for 
females than males. Older males‟ opiate-related DRD rate was 1.9 (1.24 to 2.40) per 
100 current IDUs without or 1.3 (0.94 to 1.64) with inclusion of recent HCV 
diagnoses.  
 
If, indeed, Scotland had only 25000 current IDUs in 2006, with only 8200 of them 
aged 35+ years, the opiate-related DRD rate is higher among this older age group than 
has been appreciated hitherto. There is counter-balancing good news for the public 
health:  the hitherto sharp increase in older current IDUs had stalled by 2006.  
[229 words] 
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Key points: None of the four Scottish data-sources used to estimate how many IDUs 
there were in 2006 listed more than 15% of them and three each listed fewer than 5%. 
Since the majority of Scotland‟s IDUs were „hidden‟ from data-sources that typically 
launch studies of IDUs‟ mortality, it is unsurprising if record-linkage studies 
estimating listed IDUs‟ death-rates give different answers than estimation of opiate-
related death-rates by sex and age-group for all injectors revealed, as here, by capture-
recapture estimation. Importantly, differences between capture-recapture data-sources 
in how IDU-status is assigned may also be estimation-critical, as we have illustrated. 
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INTRODUCTION 
Scotland’s injecting drug users: By applying capture-recapture (CRC) methods to 
the cross-counts from four Scottish data-sources which list current injecting drug 
users (IDUs), our aim is to provide an update for 2006 on Scotland‟s prevalence of 
current IDUs, including by gender and age-group (15-34, 35+ years). We also make 
comparison with earlier estimates for Scotland in 2000 and 2003. In particular, we 
determine if the 21
st
 century increase in Scotland‟s current IDUs aged 35+ years has 
begun to plateau. The increase was mainly a consequence of the ageing of Scotland‟s 
epidemic wave of IDU-initiates in the early to mid 1980s.  
 
Following work by Bird and Robertson (2011) on the toxicology of Scotland‟s drugs-
related deaths (DRDs), we have improved our computation of DRD rates per 100 
current IDUs by accessing toxicology results directly to obtain, as numerator, the 
numbers of opiate-related DRDs in 2006+2007 – rather than our earlier reliance on 
approximation, see King et al. (2009). It remains problematic that IDU-risk is not 
reliably ascribed for each DRD and so IDU-related DRDs have to be inferred – here 
as opiate-related DRDs.  
 
Quality-assurance in opiate substitution therapy was achieved in Scotland by 2000 
(Strang et al., 2010) and so stability, rather than further decrease, in opiate-related 
DRDs per 100 current IDUs in Scotland would be unsurprising. However, debate 
continues about how greatly gender and age-group influence DRD rates per 100 
current IDUs and we provide new data on this issue. 
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One of four data-sources that Scotland‟s capture-recapture analyses rely upon is 
recent Hepatitis C virus (HCV) diagnoses in persons who have acknowledged 
injecting as their HCV risk-factor. However, IDU-risk is not synonymous with current 
injecting. Increasingly, there has been outreach to Scotland‟s former IDUs, born in 
1956-75, to engage them in HCV testing because many (over half) are HCV carriers 
and at risk of progression to cirrhosis, see Hutchinson et al. (2005), Hepatitis C 
Action Plan for Scotland Phase II: April 2008 – March 2011 (2008), and Bird et al. 
(2010a). Earlier still, in their April 2004 consensus statement on HCV, the Royal 
College of Physicians of Edinburgh had advocated that: “High priority for case 
finding should be given to former injecting drug users.” We have therefore had to 
consider that IDU-risk, particularly in respect of HCV diagnoses since 2004, has 
encompassed both current and former IDUs and, increasingly, could lead us to over-
estimate Scotland‟s number of current IDUs aged 35+ years. Accordingly, we provide 
two sets of prevalence results for current IDUs in 2006, the second by applying CRC 
methods to cross-counts from only three data-sources, that is: after exclusion of recent 
HCV diagnoses. We compare these results with previous estimates of current IDUs in 
2000 and 2003 which were obtained using similar CRC analyses including the HCV 
database as one of the data sources. 
 
Before proceeding, we briefly provide some background on three aspects of IDUs‟ 
DRD-rate, namely: i) CRC methods to estimate IDU-prevalence; ii) drug-induced 
deaths (see also Advisory Council on the Misuse of Drugs, 2000 and National Forum 
on Drug-Related Deaths in Scotland, 2007); and iii) studies of the mortality of listed 
IDUs.   
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In November 2011, the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) issued its review of Mortality related to drug use in Europe: public 
health implications (http://www.emcdda.europa.eu/publications/selected-
issues/mortality). The EMCDDA had utilized: i) national estimates of problem opioid 
users or injecting drug users (IDUs), which are typically derived by CRC methods, 
see Fienberg (1972), Frischer et al. (1993), King and Brooks (2001) and below; ii) 
national statistics on drug-induced deaths, some subject to substantial registration 
delays (see http://www.rss.org.uk/site/cms/newsarticle.asp?chapter=15&nid=33; 
accessed on 12 April 2012), others to under-reporting, see Janssen (2011); and iii) 
studies of mortality among problem drug users who, for the most part, were enlisted 
because they had attended drug treatment services, been arrested, or been diagnosed 
with a blood-borne virus (see, for example: Strang et al., 2003; Davoli et al., 2007; 
Hickman et al., 2009; McDonald et al., 2009; Bird on behalf of European COSMO 
Workshop, 2010; Kimber et al., 2010; Gibson et al., 2011; Merrall et al., 2012). 
Follow-up in mortality studies was either by consent or by record-linkage with 
safeguards against deductive disclosure about individuals‟ identity, see Bird and 
Hutchinson (2003).  
 
Capture-recapture methods to estimate IDU prevalence: In Scotland, CRC 
methods were first used by Frischer et al. (1993) to estimate Glasgow‟s number of 
current IDUs in the late 1980s: see also Frischer et al. (1997). Covariate-adjusted, 
Bayesian, and even single-list (Mascioli and Rossi, 2008; Hay and Smit, 2003) CRC 
methods have been variously deployed to estimate the number of IDUs. There has 
been serial use of CRC methods in Scotland and England (King et al., 2009; Hay et 
al., 2009; Surveys, Design and Statistics Subcommittee, 2008); use in resource-poor 
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countries, as reviewed by van Hest et al. (2011), in Eastern Europe (Uuskula et al., 
2007), in multiple cities of England or France (Hickman et al., 2004; Vaissade  and 
Legleye, 2009); and within a primary care trust where CRC analysis focused 
additionally on IDUs who were matchable to the primary care register (“registered”) 
and for whom 2–year mortality could therefore be ascertained directly (Hickman et 
al., 2009).  Hickman et al. (2009) neatly showed that the upper 95% confidence limit 
for the number of “registered” IDUs was below the lower 95% confidence limit for 
the totality of IDUs in the Bristol primary care trust. Whereas 2348 (72%) of around 
3300 “registered” IDUs were listed on one or more of three data-sources, only 638 
(28%) were of Bristol‟s roughly 2,300 “unregistered” IDUs. Neither death-rates nor 
how demography influences them need coincide between “registered” and 
“unregistered” IDUs, as a much higher proportion of the latter was hidden from 
services and, therefore, unlisted. 
 
Drug-induced deaths: The EMCDDA report registered surprise - which we do not 
share (Bird et al., 2010b) - that, despite harm reduction measures such as opiate-
substitution therapy, see Kimber et al. (2010), the numbers of drug-induced deaths 
have remained stable or increased in most countries since 2003. By contrast, Bird et 
al. (2003) and King et al. (2005; 2009; 2012) have drawn attention not only to higher 
drug-related death (DRD) rates per 100 IDUs in older IDUs but also to higher 
numbers of DRDs at older ages consequent upon the ageing (to 35+ years) in the 21
st
 
century of epidemic waves of IDUs who had commenced injecting in the 1980s – 
earlier in Scotland, for example, than in England. 
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Record-linkage studies of mortality: Record-linkage studies (and some cohorts) 
have been crucial for identifying listees‟ time-specific hazards for DRDs, such as:  in 
the first and second fortnight after release from prison (Bird and Hutchinson, 2003; 
Farrell and Marsden, 2008; Merrall et al, 2010; Lyons et al., 2011); after inpatient 
detoxification (Strang et al., 2003), or in the first four weeks of, or after expiry of, 
methadone script (Cornish et al., 2010). See Kimber et al. (2010) for competing 
impacts of opiate substitution therapy on an Edinburgh IDU cohort‟s mortality and 
length of injecting career. Such studies have also highlighted demographic and other 
influences on listees‟ cause-specific mortality (McCowan et al., 2009; Bird on behalf 
of European COSMO Workshop, 2010; Merrall et al, 2012), and have been deployed 
to explain the divergence in mortality rates at ages 15-54 years between Scotland and 
England (Bloor et al., 2008), or to investigate how the relative importance of specific 
causes of death changes over time (McDonald et al., 2010; Gibson et al., 2011). 
 
Published CRC studies for current IDUs typically reveal that a low to modest 
percentage (5% to 40%) only is listed on any particular data-source. The same data-
sources tend to be used not only for CRC studies but also for mortality studies on 
IDUs who have accessed services. It is therefore plausible that DRD-rates and 
cofactors in unlisted current IDUs may differ from those who were listed (or 
captured).  
 
Estimation of Scotland’s DRD rates per 100 current IDUs: Rather than adhering 
just to record-linkage or cohort studies, important although these undoubtedly are, we 
have also tackled the estimation of Scotland‟s DRD-rates per 100 current IDUs by 
bringing together national statistics on drug-induced deaths (as numerator) and 
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Bayesian CRC estimates of current IDUs (as denominator). In doing so, we have 
taken account of IDUs‟ demography, namely: region, sex and age-group, see King et 
al. (2005, 2009, 2012). Our Bayesian CRC analyses allow for differential source by 
source, source by cofactor, and cofactor by cofactor capture-propensities, otherwise 
known as pairwise interactions. 
 
Previously, see King et al. (2009), we estimated the number of Scotland‟s IDUs in 
2003 as 27400 to nearest 100 (95% credible interval: 20700 to 32100). Our estimate 
was higher than had emerged when pairwise interactions were restricted to a 
maximum of two, see Bird et al. (2010b). Intriguingly, the posterior distribution for 
Scotland‟s IDUs in 2003 was bimodal with the lower mode around 21,000 which was 
similar to the estimate released by the then-Scottish Government. We were concerned 
by an apparent paradox: 
 
that, if the lower mode were genuine, the implication would 
be that Scotland‟s drugs-related death (DRD) rate per 100 IDUs had increased since 
2000 – despite harm reduction efforts, see Bird et al. (2010b). 
 
Not until 2010 did we have access to the cross-counts from Scotland‟s CRC study in 
2006 which have enabled us to apply Bayesian CRC analysis to estimate Scotland‟s 
current IDUs in 2006 with the same prior assumptions as in 2003 and 2000, see King 
et al. (2009; 2005).  
 
The new estimates are important for four reasons. First, CRC prevalence estimates, 
and consequently DRD rates per 100 current IDUs, are shown to be sensitive to the 
exclusion (as data-source) of recent HCV diagnoses, for whom IDU-risk may relate to 
past injecting. Secondly, we improved on how we count opiate-related DRDs by 
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accessing toxicological results directly, in the manner of Bird and Robertson (2011). 
The underlying, unproven assumption remains: that all Scotland‟s opiate-related 
DRDs pertain to current IDUs. Thirdly, Scotland‟s regions have changed so that the 
new geographical definition which applies from 2006 is Greater Glasgow and Clyde 
(GGC) versus the rest of Scotland whereas previously published Bayesian estimates 
were for Greater Glasgow versus elsewhere in Scotland.  
 
METHODS 
Drugs-related deaths: Since 2000, Scotland‟s deaths are coded by the 10th edition of 
the International Classification of Diseases (ICD10). We investigated Scotland‟s 
DRDs in 2006+2007 as defined UK-wide, see Jackson (2001) and General Register 
Office for Scotland, which comprised deaths involving drugs or attributed to drug 
dependence: mental and behavioural disorders due to psychoactive substance misuse 
(ICD10: F11-F16, F19); accidental poisoning (ICD10: X40-X44); intentional self-
poisoning by drugs, medicaments and biological substances (ICD10: X60-X64); 
assault by drugs, medicaments and biological substances (ICD10: X85); and events of 
undetermined intent, poisoning (ICD10: Y10-Y14). Opiate-related DRDs are DRDs 
for whom toxicology revealed the presence of heroin/morphine or methadone.  
 
Data-sources and designation as current IDU: In Scotland‟s national CRC study 
for current IDUs in 2006, individuals were recorded by four possible data-sources: 
social enquiry reports, DS1 (designation: if drug injecting was noted as an issue); 
hospital records, DS2 (ICD10 diagnoses indicative of injecting: 135, 180 and L02); 
drug treatment agencies (DTAs), DS3 (where designation was based on having 
injected in the past month); and recent Hepatitis C virus (HCV) diagnoses, DS4, for 
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whom designation was based on self-reported IDU-risk (past or present). Each 
individual was categorised by age (<35/35+), gender (male [M]/female [F]) and 
region (Greater Glasgow and Clyde [GGC]/rest of Scotland [rest]). In total, 5670 
unique individuals were observed from the combination of sources. The cross-counts 
are provided in Table 1 together with summary statistics. 
 
Analysis: Bayesian analysis allowed the incorporation of independent, expert prior 
information on the total IDU-population size. The additional external information 
related to the observed number of opiate-related DRDs coupled with a prior interval 
for IDUs‟ DRD rate, which provided a prior interval for Scotland‟s number of IDUs. 
We used hierarchical log-linear models (Fienberg, 1972) to fit the cross-count data 
provided in Table 1.  
 
We considered approximately 2 million log-linear models: those corresponding to all 
possible combinations of pairwise interactions (that is: interactions such as source by 
source, category by category and source by category). Pairwise interactions represent 
capture-dependencies between the data-sources and/or categorical variables. For 
example, a positive interaction between data-sources DS2 and DS3 indicates that 
being observed by data-source DS2 renders the individual more likely to be observed 
on DS3, and vice versa. A computationally intensive algorithm (Reversible jump 
Markov chain Monte Carlo) was used, see Green (1995), to explore the set of 
admissible models and obtain posterior summary statistics of the parameters of 
interest within each model including IDU-population size (median, mean and 95% 
“symmetric” credible interval, CI) for each of eight strata defined by region, gender 
and age-group as well as Scotland-wide. In addition, this algorithm permits the 
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estimation of the corresponding posterior model probabilities, which is a quantitative 
comparison of competing models, and thereby allows model-averaged estimates to be 
obtained that incorporate both parameter and model uncertainty in the population 
estimates. Model-averaged estimates are obtained by weighting the estimates from 
each individual model by the corresponding posterior model probabilities (King and 
Brooks, 2001). Of technical interest, simulations were run for 50 million iterations 
with the first 10% discarded as burn-in. To reduce memory-storage, simulations were 
thinned every 50 iterations. 
 
Priors: The prior estimate for total IDU-population size was based on the number of 
opiate-related DRDs in 2006+2007 (any deaths with mention of heroin/morphine or 
methadone) and using the prior 90% interval of (0.5%, 2%) for IDUs‟ DRD-rate. 
Assuming a log-Normal prior on the total IDU-population, we specified the prior with 
median 34800 and 90% interval (17400, 69600). For all other parameters, we 
specified uninformative priors. As a sensitivity check, we repeated the analysis by 
specifying only vague uniform prior on the total IDU-population size, and confirmed 
that the CRC data dominated the informative prior anyway. 
 
Exclusion of fourth data-source:  A further, more critical sensitivity analysis was 
undertaken to investigate the effect of excluding one of the four Scottish data-sources, 
see Figure 1. Designation as current IDUs differed between data-sources: strictest for 
DTAs (DS3), least stringent for recent HCV diagnoses (DS4). We report the results of 
the sensitivity analysis when recent HCV diagnoses were excluded. Of the four data-
source exclusions, only DS4 was associated with a high probability, 0.92, that IDU-
population size was thereby reduced (and the reduction was primarily for IDUs aged 
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35+ years, as anticipated). The other probabilities were: 0.66, 0.35 and 0.61 for 
exclusion of DS1, DS2 and DS3 respectively. 
 
 
RESULTS 
Prevalence of current IDUs: Using all four data-sources first, and after exclusion of 
recent HCV diagnoses (DS4), we present, in Table 2, the model-averaged posterior 
median [mean] and symmetric 95% CI for the total IDU-population size and for each 
cross-classification of covariates. All posterior densities had a single uncomplicated 
mode. 
 
Table 3 shows that, irrespective of inclusion/exclusion of DS4, Scotland‟s estimated 
mean numbers of current IDUs aged 15-34 years were closely similar for 2000
 
(King 
et al., 2005), 2003 (King et al., 2009) and 2006, namely: 22300 in 2000; 19900 in 
2003; and 19300/18700 in 2006 (to nearest 100). By contrast, whether the sharp 
increase in Scotland‟s estimated number of current IDUs aged 35+ years that was 
apparent between 2000 and 2003
 
has continued into 2006 depends critically on 
inclusion/exclusion of DS4: from 4100 in 2000 through 7500 in 2003 to 12400/6300 
in 2006 (to nearest 100). For both genders, Scotland had a nearly 3-fold increase in its 
older IDUs between 2000 and 2006 when using all four data-sources; but the rise 
stalled in 2006 if recent HCV diagnoses are excluded from our CRC analysis.  
 
Irrespective of inclusion/exclusion of DS4, we note that the posterior median [mean] 
male to female IDU ratio was 2.9 [2.9/3.0] with 95% symmetric credible interval 
respectively (2.7, 3.1)/(2.6, 3.6) for DS4 included/excluded.  
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Opiate-related DRDs per 100 current IDUs: Scotland‟s numbers of opiate-related 
DRDs in 2006+2007 (those with any mention of heroin/morphine or methadone) were 
used in conjunction with stratum-specific prevalences in Tables 4 and 5 (respectively 
according to inclusion and exclusion of DS4) to provide, for strata defined by region, 
gender and age-group, an estimated annual opiate-related DRD rate per 100 current 
IDUs and 95% credible interval. The higher rates are in Table 5, on which we base 
our initial commentary.  
 
Table 5 confirms the pattern (but not level) of IDUs‟ DRD-rates in King et al. (2009), 
namely: among younger IDUs, males‟ opiate-related DRD rate is substantially higher 
than for females. But, among IDUs aged 35+ years, females do not experience a 
significantly lower opiate-related DRD rate.  
 
For older males, there were 1.9 opiate-related DRDs annually per 100 current IDUs 
(95% CI: 1.2 to 2.4) by exclusion of DS4, but 1.3 per 100 current IDUs (95% CI: 0.9 
to 1.6) otherwise, see Table 4.  
 
For younger males, the rates were respectively 1.4 (95% CI: 1.0 to 1.8) in Table 5 and 
1.3 (95% CI: 1.0 to 1.5) in Table 4. 
 
Please see Appendix for discussion of capture propensities in 2006. 
DISCUSSION 
Scotland‟s CRC studies in 2000, 2003 and 2006 have each relied on DS4, recent HCV 
diagnoses (with self-reported IDU-risk taken as proxy for current IDU), as one of four 
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data-sources. This reliance has been more questionable since the HCV consensus 
statement by the Royal College of Physicians of Edinburgh in April 2004 that “high 
priority for case finding should be given to former injecting drug users” and the 
conclusion of Hutchinson et al. (2005) that Scotland‟s HCV testing and treatment 
should focus on older former IDUs because of their high HCV carriage, likely 
progression towards cirrhosis, and negligible risk of HCV re-infection. Moreover, 
increase in such testing was a specific aim in Phase II of Scotland‟s Hepatitis C 
Action Plan, which had prompted us to check more recent reliance on DS4 in 2009 
and to back-check on 2006. Dramatically, the 2006 CRC estimation of Scotland‟s 
older current IDUs is reduced by a third when DS4 is excluded as an inadmissible 
data-source for identifying current IDUs. Further work, both methodological and 
epidemiological, is ongoing to determine if we can re-instate at least partial use of 
DS4-listed IDUs, only some of whom are current IDUs. 
 
With DS4, there has been a near trebling in Scotland‟s number of current IDUs who 
are aged 35+ years between 2000 and 2006. Without DS4, the doubling in Scotland‟s 
number of current IDUs between 2000 and 2003 appears to have stalled by 2006. 
Scotland has seen a doubling between 2000 and 2006 in DRDs in those aged 35+ 
years (206 in 2000+2001, 255 in 2003+2004, 409 in 2006+2007, 555 in 2009+2010), 
see General Register Office for Scotland (2009) and Drug Misuse Statistics Scotland 
2010 (2011). Corresponding statistics on opiate-related DRDs in those aged 35+ years 
are not routinely published but were: 140 in 2000+2001, 169 in 2003+2004, 306 in 
2006+2007, 424 in 2009+2010. Neither rise is as dramatic as Scotland‟s estimated 
increase in older current IDUs by inclusion of DS4. 
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As shown in Tables 4 and 5, the counterpoint to lower estimated prevalence of older 
current IDUs is acknowledgement that their experienced estimated rate of opiate-
related DRD per 100 current IDUs is higher (1.9; 95% credible interval: 1.2 to 2.4). If 
older current IDUs‟ rate of opiate-related DRD is also higher, even for males, than at 
15-34 years of age, then Scotland‟s continued, albeit slower, increase in older opiate-
related DRDs in and beyond 2006+2007 may be accounted for more by the said 
higher rate than by increasing prevalence. 
 
For the 2003 estimation of opiate-related DRDs per 100 current IDUs, King et al. 
(2009) assumed that 80% of Scotland‟s DRDs at ages 15-44 years were opiate-related 
but only 20% thereafter. Although we have now improved the toxicological basis for 
the numerator, for opiate-related deaths in the younger age-group, there was about a 
25% increase between the estimated rates for 2003 and Table 4‟s rates for opiate-
related DRD per 100 IDUs in 2006 but consistency in the older age-group. However, 
by exclusion of DS4 as an admissible data-source together with direct access to 
toxicology, we should conclude that opiate-related DRD rates have increased by about 
a third in all three summary strata (females aged 15-34 years, males aged 15-34 years, 
all aged 35+ years) between 2003 and 2006. The latter has more uncomfortable 
connotations for public health policy than to have supposed that the increase in 
Scotland‟s DRDs in the older age-group was primarily a consequence of the ageing of 
an epidemic wave of IDU-initiates in the early to mid 1980s. 
 
Females‟ opiate-related DRD rate per 100 IDUs at 15-34 years of age is about half 
that of their male counterparts but, in Scotland, this female advantage is not 
maintained into the older age group. A more powerful Bayesian analysis, with no 
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reliance on recent HCV diagnosis, of current IDUs‟ opiate-related deaths in England 
in 2005/06 (King et al., 2012) offers a gender-qualification
 – whereby there may be 
some residual, but reduced, female advantage in older age.  
 
The sensitivity of Scotland‟s estimated prevalence of older current IDUs to 
inclusion/exclusion of recent HCV diagnoses as an admissible data-source, wherein 
IDU-risk was past or current, shows that attention needs to be paid to how current 
IDUs are identified in cross-linked CRC data-sources. Failure to recognise, or capture, 
all current IDUs within a particular data-source may be a less serious problem than 
mis-attribution of current IDU-status to past injectors. Differences in prevalence 
estimates per stratum with/without inclusion of Scotland‟s recent HCV diagnoses 
were primarily as anticipated: in the older cohort. 
 
Early in 2012, Scotland released cross-counts to enable Bayesian estimation of its 
numbers of current IDUs in 2009, for which the present analysis, unlike that for 2003, 
see King et al. (2009), is a geographically-consistent benchmark. The CRC prevalence 
estimates for 2009, like those for 2006, are sensitive to exclusion (as data-source) of 
recent HCV diagnoses. 
 
 
Besides how current IDU is defined, it is important to consider and, as Hickman et al 
(2004) did, to report listees‟ representativeness when we are tempted to generalize 
from DRD-rates or prognostic factors that were revealed by record-linkage studies of 
listed IDUs‟ mortality. Even the largest of Scotland‟s four CRC source-datasets 
(DTAs) listed only an estimated 11%/14% (3504 out of 31700/25000) of Scotland‟s 
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IDUs in 2006 (with 95% credible intervals of (9%, 14%)/(10%, 17%)) whereas, for 
example, the needle and syringe programme of Bristol‟s primary care trust had listed 
35% (1929) of that trust‟s current IDUs and its DTAs in combination with laboratory 
records had listed 43% (2365).  
 
Explanations for the lower age-differential in DRD-rates seen in European cohort 
studies, see for example Bird on behalf of European COSMO Workshop (2010), as 
compared with bringing together national numerators and denominators include: 
firstly, that sex and age-group may interact (as here) in their influence on opiate-
related DRD-rate; secondly, the limited representativeness of those enlisted into 
cohorts or record-linkage studies; and thirdly, the impact of harm-reduction 
interventions offered to listees, especially if designed to mitigate DRD-risk, see 
Kimber et al. (2010), whereas the unlisted have not accessed these and so may have 
correspondingly higher unmitigated risk.  
 
The third of Scotland‟s serial four data-source Bayesian CRC estimations has been 
complicated by the IDU-risk of older recent HCV diagnoses being, to an increasing 
extent, non-current due to the early impact of findings by Hutchinson et al. (2005) on 
high Hepatitis C carriage by older former IDUs which have since been formalised as 
the testing and treatment aims in Phase II of Scotland‟s Hepatitis C Action Plan for 
2008-11. 
 
If, indeed, Scotland had only 25000 current IDUs in 2006, only 8200 of them aged 
35+ years, their opiate-related DRD rate is higher at 1.9 (95% CI: 1.2 to 2.4) per 100 
older current IDUs has been appreciated hitherto. The counter-balancing good news in 
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public health terms is, as shown in Table 3, that the hitherto sharp increase in older 
current IDUs had stalled by 2006. [3961 words] 
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Table 1: Number of individuals observed: (a) in each combination of data-sources per 
demographic cross-classification; (b) by each demographic characteristic (GGC = Greater 
Glasgow & Clyde; Rest = rest of Scotland), or data-source (DS1 = social enquiry reports; 
DS2 = hospital records; DS3 = drug treatment agencies; DS4 = recent HCV diagnoses). 
(a) 
DS1 DS2 DS3 DS4 Male 
<35 
GGC 
Male 
35+ 
GGC 
Female 
< 35 
GGC 
Female 
35+ 
GGC 
Male 
<35 
Rest 
Male 
35+ 
Rest 
Female 
< 35 
Rest 
Female 
35+ 
Rest 
Total 
0 0 0 0 ? ? ? ? ? ? ? ? ? 
1 0 0 0 97 60 41 13 278 67 86 12 654 
0 1 0 0 77 111 48 34 173 144 108 56 751 
1 1 0 0    0  0 5 0 19 
0 0 1 0 292 149 117 26 1379 431 584 114 3092 
1 0 1 0 7  5 0 110 16 53  198 
0 1 1 0 6 5 7  39 27 24 9 121 
1 1 1 0  0 0 0     8 
0 0 0 1 122 135 48 38 134 104 78 25 684 
1 0 0 1    0 6 0  0 13 
0 1 0 1 5 10   7 7 5  43 
1 1 0 1 0  0 0  0 0 0  
0 0 1 1     27 13 18  69 
1 0 1 1  0 0 0 5  0 0 7 
0 1 1 1  0 0 0     9 
1 1 1 1 0 0 0 0 0 0 0 0 0 
    620 482 276 120 2167 812 968 225  
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Counts 1 to 4 have been replaced by blanks in (a) pending permission for disclosure. 
(b) 
Summary statistics 
by data-source, or 
characteristic 
DS1 DS2 DS3 DS4 Male Female < 35 35+ GGC Rest 
 IDUs observed 901 953 3504 827 4081 1589 4031 1639 1498 4172 
 
Footnote to Table 1: It took 9 months in 2010 for us to be given access to the cross-counts for 2006, 
and we still do not have permission to disclose low cross-counts. Thus counts of 1 to 4 have 
temporarily been replaced by blanks. We hope that, by the time of publication, redaction should be 
unnecessary as a) we consider it good practice for other analysts to have access to basic data and b) 
there is no possibility of deductive disclosure about individuals. 
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Table 2: Posterior median [mean] and 95% “symmetric” credible intervals (CI) rounded to 
nearest 100 for number of current IDUs, overall and per-stratum: M = male, F = female; 15-
34 and 35+ denote age-groups; GGC = Greater Glasgow and Clyde; Rest = rest of Scotland. 
Current 
IDUs per 
stratum: to 
nearest 100 
2006: all 4 data-sources 2006: having excluded recent 
HCV diagnoses 
Model-averaged 
median [mean]  
95% CI   Model-averaged 
median [mean]  
95% CI   
M, 15-34, 
GGC 
  4200   [  4300] (3000,   6000)   3300   [  3400] (2600,   4900) 
M, 35+,    
GGC 
  4500   [  4600]  (3100,   6500)   2800   [  2900]  (2100,   4400) 
F , 15-34, 
GGC 
  1800   [  1800] (1200,   2600)   1300   [  1300] (1000,   2000) 
F , 35+,    
GGC 
  1100   [  1100] (  700,   1600)     600   [    600] (  400,   1000) 
M, 15-34, 
Rest 
  9100   [  9200] (7100, 11300)   8200   [  8400] (6800, 11700) 
M, 35+,    
Rest 
  5400   [  5400] (3800,   7000)   3900   [  4000] (3000,   5800) 
F , 15-34, 
Rest 
  3900   [  3900] (3000,   4800)   3300   [  3400] (2700,   4700) 
F , 35+,    
Rest 
  1300   [  1300] (  900,   1700)     900   [    900] (  700,   1300) 
Total 31500   [31700]  (24900, 38700) 24300   [25000]  (20700, 35000) 
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Table 3: Posterior median [mean] and 95% “symmetric” credible intervals (CI) 
rounded to nearest 100 for the number of current IDUs per gender and age-group 
stratum in 2000, 2003 and 2006:  15-34 and 35+ denote the age-groups. 
 
Gender & age-group 
stratum in serial 
Bayesian capture-
recapture analyses 
Model-averaged median for Scotland’s current IDUs 
2000
1 2
 
(from King 
et al., 2005) 
2003
2
 
(from King 
et al., 2009) 
2006: all 4 data-sources 
2006: having excluded recent HCV 
diagnoses 
Median [mean] 95% CI 
Male,     15-34 16000  13400 13400   [13500] 
11500   [11800] 
(10600, 16500) 
(  9500, 16500) 
Male,     35+    3300   5800 9900 [10000] 
6700   [  6900] 
(  7300, 12800) 
(  5200, 10100) 
Female , 15-34   6300    6500 5700 [  5800] 
  4600   [  4700] 
(  4500,   7000) 
(   3700,   6600) 
Female , 35+     800   1700 2400 [  2400] 
1500   [  1600] 
(  1700,   3100) 
(  1100,   2300) 
1
 Footnote to Table 3: Outwith Greater Glasgow, four island and other health areas 
did not take part in the 2000 CRC study, to account for which a modest proportionate 
adjustment (by 1.15) was made by King et al. (2005). Also, only two CRC data-
sources (social enquiry reports; recent HCV diagnoses) in 2000 were the same as in 
2003 and 2006; and the numerator used was all DRDs rather than opiate-related 
DRDs. 
2
 Footnote to Table 3: The estimates for 2000 and 2003 included the HCV database as 
a data source in the CRC analyses. 
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Table 4: Posterior median [mean] and 95% “symmetric” credible intervals (CI) by 
gender and age-group stratum for the annual opiate-related DRD rate per 100 current 
IDUs in 2006 – all 4 data-sources in play. 
 
 
Stratum 
Current IDUs: model-
averaged median [mean]:  
to nearest 10 
Opiate-related  
DRDs in 
2006+2007 
Annual mean 
opiate-related DRD rate 
per 100 current IDUs  
(95%CI) 
All Scotland: summary strata 
Female,  
15-34 
               5720   [  5750]                   57 0.50 (0.40, 0.62) 
Male,  
15 - 34 
             13440   [13530]                 333 1.25 (0.99, 1.53) 
Male & Female 
35+ years 
       12280   [12390] 
 
          306 
 
1.24 (0.90, 1.59) 
 
All Scotland: Males 
15 - 34              13440   [13530]                 333 1.25 (0.99, 1.53) 
35+ years                9900   [  9990]                 251 1.28 (0.94, 1.64) 
All Scotland: Females 
15 - 34                5720   [  5750]                   57 0.50 (0.40, 0.62) 
35+ years                2380   [  2400]                   55 1.17 (0.84, 1.52) 
 
Greater Glasgow & Clyde: Males 
15 - 34                4180   [  4330]                115 1.37 (0.91, 1.83) 
 33 
35+ years                4450   [  4600]                114 1.29 (0.82, 1.74) 
Greater Glasgow & Clyde: Females 
15 - 34                1770   [  1830]                  26 0.73 (0.48, 0.98) 
35+ years                1060   [  1090]                  26 1.24 (0.78, 1.71) 
 
Rest of Scotland: Males 
15 - 34                9140   [  9200]               218 1.20 (0.94, 1.50) 
35+ years                5360   [  5390]               137 1.30 (0.94, 1.71) 
Rest of Scotland: Females 
15 - 34                3900   [  3920]                 31 0.40 (0.31, 0.50) 
35+ years                1300   [  1310]                 29 1.14 (0.81, 1.51) 
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Table 5: Posterior median [mean] and 95% “symmetric” credible intervals (CI) by 
gender and age-group stratum for the annual opiate-related DRD rate per 100 current 
IDUs in 2006 – after exclusion of recent HCV diagnoses (data-source DS4). 
 
Stratum 
Current IDUs: model-
averaged median [mean]:  
to nearest 10 
Opiate-related  
DRDs in 
2006+2007 
Annual mean 
opiate-related DRD rate per 100 
current IDUs  (95%CI) 
Also from King et al. (2009) for 2003 
All Scotland: Summary Strata 
Female,  
15-34 
               4600   [  4720]                   57 0.61 (0.43, 0.76) 
2003: 0.38 (0.31, 0.49) 
Male,  
15 - 34 
             11480   [11810]                 333 1.43 (1.01, 1.75) 
2003: 0.98 (0.81, 1.25) 
Male & Female 
35+ years 
               8180   [  8480]                 306 1.85 (1.24, 2.37)  
2003: 1.21 (0.95, 1.63) 
 
All Scotland: Males  
15 - 34              11480   [11810]                 333 1.43 (1.01, 1.75) 
2003: 0.98 (0.81, 1.25) 
35+ years                6680   [  6920]                 251 1.86 (1.24, 2.40) 
2003: 1.22 (0.95, 1.64) 
All Scotland: Females 
15 - 34                4600   [  4720]                   57 0.61 (0.43, 0.76) 
2003: 0.38 (0.31, 0.49) 
35+ years                1500   [  1560]                   55 1.82 (1.19, 2.41) 
2003: 1.18 (0.91, 1.62) 
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Greater Glasgow & Clyde: Males 
15 - 34                3280   [  3390]                115 1.74 (1.17, 2.21) 
35+ years                2800   [  2910]                114 2.02 (1.30, 2.67) 
Greater Glasgow & Clyde: Females 
15 - 34                1310   [  1350]                  26 0.99 (0.66, 1.28) 
35+ years                  610   [    640]                  26 2.12 (1.33, 2.91) 
 
Rest of Scotland: Males 
15 - 34                8190   [  8420]               218 1.32 (0.93, 1.60) 
35+ years                3880   [  4010]               137 1.75 (1.17, 2.25) 
Rest of Scotland: Females 
15 - 34                3290   [  3370]                 31 0.47 (0.33, 0.58) 
35+ years                  890   [    920]                 29 1.62 (1.08, 2.14) 
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APPENDIX on Capture Propensities 
 
Using four data-sources: Posterior marginal probabilities of the presence of each 
possible two-way interaction are shown in Table A1. See King et al.
 
(2009) for the 
2003 version, but recall that regional geographies differ between the 2003 and 2006 
analyses. We note that whereas in 2003 the interaction between hospital records and 
age was, perhaps surprisingly, non-essential, its inclusion in the 2006 analysis 
conveys that hospital record was more likely for IDUs aged 35+ years. In 2006, the 
only non-essential source by age interaction was recent HCV diagnosis (as also in 
2003). Finally, age-group by gender was a key interaction which signalled, as in 2003, 
that the male to female ratio was less extreme for younger IDUs.  
 
Table A1: Posterior probability of each two-way interaction, with its posterior mean 
(standard deviation) when present. DTA = Drug Treatment Agency 
Interaction in 2006:  vs 2003 Posterior probability Effect size: Mean (sd) 
Source by Source 
DS1 (social) x DS2 (hospital): 
Lost significance 
0.083   0.002 (0.017)  
DS1 (social) x DS3 (DTA): 
Effect doubled in 2006 
1.000    0.193 (0.041)  
DS1 (social) x DS4 (HCV) 0.079    0.000 (0.017)  
DS2 (hospital) x DS3 (DTA): 
Effect at least halved in 2006 
0.700    0.068 (0.054)  
DS2 (hospital) x DS4 (HCV) 0.998    0.212 (0.048)  
DS3 (DTA) x DS4 (HCV) 0.087  -0.001 (0.017)  
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Covariate by Covariate 
Age (35+) x Sex (Female) 1.000  -0.144 (0.018)  
Age (35+) x Region (Rest) 1.000  -0.134 (0.017)  
Sex (Female) x Region (Rest) 0.035   0.001 (0.004) 
Source by Covariate 
DS1 (social) x Age (35+) 1.000  -0.208 (0.030)  
DS2 (hospital) x Age (35+): 
Acquired significance in 2006 
0.912   0.075 (0.034)  
DS3 (DTA) x Age (35+) 1.000  -0.178 (0.027)  
DS4 (HCV) x Age (35+) 0.133   0.006 (0.021)  
 
DS1 (social) x Sex (Female): 
Lost significance in 2003 
0.126  -0.005 (0.015)  
DS2 (hospital) x Sex (Female): 
Acquired significance in 2006 
1.000  0.104 (0.020)  
DS3 (DTA) x Sex (Female) 0.047 0.001 (0.007)  
DS4 (HCV) x Sex (Female) 0.138  0.006 (0.017) 
 
DS1 (social) x Region (Rest) 0.509  0.052 (0.062)  
DS2 (hospital) x Region (Rest) 
Lost significance in 2006 
0.320 0.031 (0.051)  
DS3 (DTA) x Region (Rest): 
Acquired significance in 2006 
1.000  0.247 (0.053)  
DS4 (HCV) x Region (Rest) 0.768  -0.092 (0.057)  
After exclusion of recent HCV diagnoses: Posterior marginal probabilities of the presence of 
each possible two-way interaction are shown in Table A2. From Table A1, two significant 
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pairwise interactions, shown above in yellow, which involved recent HCV diagnoses became 
inadmissible in Table A2, where the only other change of note is further diminished 
importance for interaction between DS2 (hospital) & DS3 (DTA).  
 
Table A2: Having excluded DS4 (recent HCV diagnoses) as data-source, posterior 
probability of each two-way interaction, with its posterior mean (standard deviation)  
when present. DS1= social enquiry reports; DS2= hospital records; DS3= drug 
treatment agencies. 
Interaction in 2006 Posterior probability Effect size: Mean (sd) 
Source by Source 
DS1 (social) x DS2 (hospital) 0.139  -0.004 (0.024)  
DS1 (social) x DS3 (DTA) 0.998    0.145 (0.043)  
DS1 (social) x DS4 (HCV) Inadmissible 
DS2 (hospital) x DS3 (DTA) 0.207    0.013 (0.036)  
DS2 (hospital) x DS4 (HCV) Inadmissible 
DS3 (DTA) x DS4 (HCV) Inadmissible 
Covariate by Covariate 
Age (35+) x Sex (Female) 1.000  -0.146 (0.020)  
Age (35+) x Region (Rest) 1.000  -0.135 (0.019)  
Sex (Female) x Region (Rest) 0.057   0.001 (0.006) 
Source by Covariate 
DS1 (social) x Age (35+) 1.000  -0.164 (0.030)  
DS2 (hospital) x Age (35+) 0.974  0.131 (0.041)  
DS3 (DTA) x Age (35+) 1.000  -0.124 (0.040)  
DS4 (HCV) x Age (35+) Inadmissible 
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DS1 (social) x Sex (Female) 0.121  -0.003 (0.013)  
DS2 (hospital) x Sex (Female) 0.997  0.123 (0.020)  
DS3 (DTA) x Sex (Female) 0.384 0.019 (0.029)  
DS4 (HCV) x Sex (Female) Inadmissible 
   
DS1 (social) x Region (Rest) 0.299  0.016 (0.029)  
DS2 (hospital) x Region (Rest) 0.096 0.001 (0.014)  
DS3 (DTA) x Region (Rest) 1.000  0.211 (0.024)  
DS4 (HCV) x Region (Rest) Inadmissible 
 
For the most part, interactions that were salient in 2003 were so also in 2006 with 
exceptions potentially reflecting changes in how current IDUs access services. Some 
of the changes, such as hospital listing, may be a consequence of the ageing of 
Scotland‟s IDU-population, others a reflection of regional variation in service 
delivery. We shall know more when the 2010 CRC analysis is complete so that a 
fourth pillar can be added to the demographic tallies of IDUs in Scotland in the 21
st
 
century.  
 
